MANAGEMENT OF ENDOCRINE DISEASE: Growth and growth hormone therapy in short children born preterm

Eur J Endocrinol. 2017 Mar;176(3):R111-R122. doi: 10.1530/EJE-16-0482. Epub 2016 Nov 1.

Abstract

Approximately 15 million babies are born preterm across the world every year, with less than 37 completed weeks of gestation. Survival rates increased during the last decades with the improvement of neonatal care. With premature birth, babies are deprived of the intense intrauterine growth phase, and postnatal growth failure might occur. Some children born prematurely will remain short at later ages and adult life. The risk of short stature increases if the child is also born small for gestational age. In this review, the effects of being born preterm on childhood growth and adult height and the hormonal abnormalities possibly associated with growth restriction are discussed, followed by a review of current information on growth hormone treatment for those who remain with short stature during infancy and childhood.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adult
  • Body Height / physiology
  • Child
  • Child, Preschool
  • Female
  • Growth Disorders / drug therapy*
  • Growth Disorders / etiology
  • Human Growth Hormone / physiology
  • Human Growth Hormone / therapeutic use*
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Small for Gestational Age / growth & development*
  • Pregnancy
  • Premature Birth / physiopathology*
  • Young Adult

Substances

  • Human Growth Hormone